AMG 334

Phase 2UNKNOWN
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rosacea

Conditions

Rosacea

Trial Timeline

Jun 9, 2020 → Aug 1, 2021

About AMG 334

AMG 334 is a phase 2 stage product being developed by Novartis for Rosacea. The current trial status is unknown. This product is registered under clinical trial identifier NCT04419259. Target conditions include Rosacea.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT04419259Phase 2UNKNOWN
NCT03974360Phase 2Completed